See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
The Oscars
Volodymyr Zelenskyy
Ukraine War
Social Media
Artificial Intelligence
Donald Trump
European Union
Stock Markets
Vladimir Putin
Catholic Church
Rugby
Infrastructure
Published • loading... • Updated

Johnson & Johnson has announced data from Phase 3 study

Summary by European Pharmaceutical Manufacturer
Johnson & Johnson has announced data from the Phase 3 ASTRO study of TREMFYA (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC).
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
European Pharmaceutical ManufacturerEuropean Pharmaceutical Manufacturer

Johnson & Johnson has announced data from Phase 3 study

Johnson & Johnson has announced data from the Phase 3 ASTRO study of TREMFYA (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC).

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

European Pharmaceutical Manufacturer broke the news in on Friday, February 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

New Brunswick, New Jersey

New Brunswick, New Jersey

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal